The ER-Luminal Domain of the HCMV Glycoprotein US6 Inhibits Peptide Translocation by TAP  by Ahn, Kwangseog et al.
Immunity, Vol. 6, 613±621, May, 1997, Copyright 1997 by Cell Press
The ER-Luminal Domain
of the HCMV Glycoprotein US6
Inhibits Peptide Translocation by TAP
Kwangseog Ahn,*§ Albrecht Gruhler,* the antigen presentation machinery have evolved (re-
viewed by FruÈ h et al., 1997). In cells infected with adeno-Begona Galocha,² Thomas R. Jones,³
Emmanuel J.H.J. Wiertz,² Hidde L. Ploegh,² virus types 2 and 5, intracellular transport of MHC class
I molecules is inhibited because of association with thePer A. Peterson,* Young Yang,* and Klaus FruÈ h*
E3-region E19 protein (Andersson et al., 1985; Burgert*The R. W. Johnson Pharmaceutical
and Kvist, 1985), which contains an ER-retention motifResearch Institute
in its cytoplasmic tail (Jackson et al., 1990). More recent3535 General Atomics Court, Suite 100
work has unraveled an astonishing diversity in the waysSan Diego, California 92121
in which members of the herpes virus family interfere²Center for Cancer Research
with MHC class I antigen presentation.Epstein Barr virusMassachusetts Institute of Technology
prevents presentation of its latency-associated tran-Cambridge, Massachusetts 02139
script EBNA-1 via a stretch of repeat elements by an³Department of Molecular Biology
unknown mechanism (Levitskaya et al., 1995). HerpesInfectious Diseases Section
simplex virus 1 and herpes simplex virus 2 express aWyeth-Ayerst Research
small cytosolic protein, the immediate early gene ICP47,Pearl River, New York 10965
which inhibits TAP-dependent peptide translocation
(FruÈ h et al., 1995; Hill et al., 1995) by competing with
peptides for binding to the cytosolic substrate-bindingSummary
site of TAP (Ahn et al., 1996b; Tomazin et al., 1996).
Human cytomegalovirus (HCMV) uses an even moreHuman cytomegalovirus (HCMV) inhibits MHC class I
complex strategy to prevent MHC class I presentation.antigen presentation by a sequential multistep pro-
The immediate early gene IE1 is not presented to T cellscess involving a family of unique short (US) region±
in the presence of the matrix protein pp65, indicating anencoded glycoproteins. US3 retains class I molecules,
antigen-specific mechanism (Gilbert et al., 1996). More-whereas US2 and US11 mediate the cytosolic degra-
over, a more general prevention of class I presentationdation of heavy chains by the proteosomes. In US6-
is mediated by severalgene products of theunique shorttransfected cells, however, intracellular transport of
(US) region (Jones et al., 1995). So far, three differentclass I molecules is impaired because of defective
gene products that independently modify the intracellu-peptide translocation by transporters associated with
lar transport of MHC class I molecules have been identi-antigen processing (TAP). Peptide transport is re-
fied. The glycoproteins US2 and US11 induce the rapidstored in HCMV mutants lacking US6. In contrast to
export of MHC class I heavy chains out of the ER into thethe cytosolic herpes simplex virus protein ICP47, US6
cytosol, where they are destroyed by the proteasomeinteracts with TAP inside the endoplasmic reticulum
(Wiertz et al., 1996a, 1996b). The related glycoproteinlumen, as shown by US6 derivatives lacking the
US3, however, retains fully assembled MHC class I het-transmembrane and cytoplasmic domains and by the
erodimers (Ahn et al., 1996a; Jones et al., 1996). As aobservation that US6 does not prevent peptides from
result of the sequential expression of US3 and US11binding to TAP. Thus, HCMV targets TAP for immune
during infection, MHC class I molecules are first retainedescape by a molecular mechanism different from that
and then degraded during the viral life cycle (Ahn et al.,of herpes simplex virus.
1996a).
Here we identify a fourth glycoprotein of the HCMVIntroduction
US region,US6, which affects antigenpresentation inde-
pendent of US2, US3, or US11 and by a different molecu-A major immune defense against viral infections is medi-
lar mechanism, despite its structural relatedness andated by cytotoxic T lymphocytes, which recognize and
similar subcellular localization. We show that US6 pre-lyse infected cells upon engagement of the T cell recep-
vents peptide loading of MHC class I molecules by inhib-tor with major histocompatibility complex (MHC) class
iting TAP-mediated peptide translocation into the ER.I molecules presenting viral peptides (Townsend and
Unlike ICP47, however, US6 inhibits TAP by acting in
Bodmer, 1989). Such peptides are generated in thecyto-
the ER lumen, without interference with the cytoplasmic
sol by proteasomes and translocated into the endoplas-
substrate-binding site of TAP. Thus, TAP inhibition by
mic reticulum (ER) by a dedicated peptide transporter,
US6 represents a novel way in which viruses escape
or TAP, where they associate with empty MHC class I
immune detection by cytotoxic T lymphocytes.
heterodimers consisting of heavy chains and b2-micro-
globulin (Lehner and Cresswell, 1996). Only MHC class Results
I molecules that have acquired peptides travel through
the Golgi compartment to the cell surface to display
Four Glycoproteins of the HCMV US Region
their antigenic load. Independently Down-Regulate MHC
Under selective pressure of this immune response, Class I Surface Expression
viral escape mechanisms that interfere at every step of
To identify proteins encoded in the US region that would
interfere with MHC class I antigen presentation, we ex-
pressed each open reading frame, tetracycline con-§Present address: Graduate School of Biotechnology, Korea Univer-
sity, Anam-dong, Sungbuk-ku, Seoul, 136±701, Korea. trolled, in HeLa cells by transient transfection. Two days
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Figure 1. MHC Class I Surface Expression in HCMV US Protein±
Expressing HeLa Cells
HeLa cells that stably express tetracycline transactivator (HtTa cells)
(Gossen and Bujard, 1992) were transiently transfected with the
indicated open reading frames of the HCMV US region (Chee et al.,
1990), which had been inserted into pUHG10.3. Control cells were
transfected with ICP47.pUHG10.3 (FruÈ h et al., 1995). For half of the
transfectants, tetracycline was removed (filled graphs) to induce US
protein expression. After 48 hr, cell surface expression of MHC class
I molecules was monitored by cytofluorometry using MAb W6/32
(Parham, 1983).
after removal of tetracycline, the surface expression of
MHC class Imolecules was analyzed by cytofluorometry
using monoclonal antibody (MAb) W6/32, which spe- Figure 2. Intracellular Transport and Thermostability of MHC Class
I Molecules in US6-Transfected HeLa Cellscifically recognizes assembled heterodimers (Parham,
Untransfected HeLa cells (top) or HtTa cells stably transfected with1983). A specific reduction of class I surface levels was
either ICP47 (FruÈ h et al., 1995) (bottom) or US6 (middle) were meta-observed only in cells transfected with US2, US3, US6,
bolically labeled for 15 min and chased for the indicated time peri-and US11 (Figure 1), whereas surface expression of
ods. After lysis in 1% NP40, lysates were divided into two aliquots
transferrin receptor as well as cotransfected CD4 was and either kept on ice or incubated at 378C for 1 hr. Heterodimeric
unaffected (data not shown). Expression of the other MHC class I molecules were immunoprecipitated with MAb W6/32
open reading frames did not affect surface expression (Parham, 1983) and treated with endoglycosidase H where indi-
cated. Unlike human fibroblast cell lines transfected with ICP47(Figure 1), even when US7±US10 were cotransfected
(York et al., 1994), class I molecules do not completely remain EndoHtogether (not shown). Inhibitionof class Iantigen presen-
sensitive in HeLa cells despite complete inhibition of TAP (FruÈ h ettation by US2, US3, and US11 is in agreement with previ-
al., 1995). It is possible that some of the haplotypes expressed inous observations (Ahn et al., 1996b; Jones et al., 1996;
HeLa cells are transported in the absence of peptides or with bound
Wiertz et al., 1996a, 1996b). Since such a function has signal sequence peptides, as described for HLA-A2.1 (Henderson
not been noted for US6 we were interested in comparing et al., 1992; Wei and Cresswell, 1992). HC, heavy chain.
the molecular mechanism of US6-mediated MHC class
I down-regulation with that of US2, US3, or US11.
indicating that US6 operated at a posttranslational level.
However, the intracellular transport of MHC class I mole-MHC Class I Molecules Are Empty
in US6-Transfected Cells cules, as analyzed by EndoH digestion, was delayed in
US6-transfected cells (Figure 2), whereas neither theTherefore, we established a stable HeLacell line in which
US6 expression can be up-regulated by tetracycline re- transport of transferrin receptor nor that of EGF receptor
was affected (data not shown). Some of the W6/32-moval and studied the biosynthesis of MHC class Imole-
cules by pulse-chase analysis (Figure 2). Similar amounts reactive material remained in the ER even after chase
periods of 60 min (Figure 2) or longer (data not shown),of W6/32-precipitable class I molecules were synthe-
sized during the 15 min labeling period both in non- whereas all class I molecules in nontransfected cells
had traveled through the Golgi by this time, as indicatedtransfected and in US6-transfected HeLa cells (left lane),
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by their EndoH resistance. Thus it seemed that US6
acted by a mechanism different from that of US2 or
US11, which reduce the half-life of heavy chains (Wiertz
et al., 1996a, 1996b).
We examined the possibility that US6 retains MHC
class I molecules similar to US3, but less efficiently.
Solubilized US3-retained MHC class I molecules are re-
sistant to increased temperatures (Ahn et al., 1996a) and
thus contain peptides (Townsend et al., 1990). However,
no class I heterodimers could be immunoprecipitated
from US6-transfected cells after the lysates were incu-
bated at 378C for 1 hr at any time of the experiment
(Figure 2). In contrast, class I molecules of nontrans-
fected HeLa cells were partially thermostable after 15
min pulse and acquired full thermostability thereafter
concomitant with their acquisition of EndoH resistance.
This result suggested that class I molecules did not
contain peptides in US6 transfectants regardless of
whether they remained in the ER or not. Thus, US6
seems to affect the maturation of MHC class I molecules
by a mechanism different from that of US3.
Figure 3. Peptide Translocation in US-Transfected HeLa CellsSince ªemptyº class I molecules can also be observed
Translocation of iodinated peptide RYNATGRL into the ER of non-in ICP47-transfected HeLa cells, we compared the intra-
transfected HtTa cells or cells stably transfected with US3 (Ahn etcellular transport and thermostability of ICP47 transfec-
al., 1996a), US11 (Ahn et al., 1996a), ICP47 (FruÈ h et al., 1995), or
tants and US6 transfectants. As shown in Figure 2, the US6 was measured after tetracycline had been removed for 24 hr
two cell lines were indistinguishable for both assays, (2tet) to induce expression. First, 0.15 U streptolysin O (Murex) was
suggesting that US6 and ICP47 prevent peptide loading activated for 10 min at 378C in 100 ml of transport assay buffer
(Neefjes et al., 1993) containing 4 mM dithiothreitol and 10 mMof MHC class I molecules by a similar mechanism.
fresh ATP. Transfected or nontransfected HeLa cells (2 3 106) were
resuspended in this solution, and after the addition of 2 3 106 cpm
US6 Prevents Peptide Translocation by TAP labeled RYNATGRL, cells were incubated at 378C for 25 min. ConA
precipitation was perfomed as described (Neefjes et al., 1993). AsSince ICP47 inhibits TAP, we examined whether US6
a control, no ATP was added and residual ATP was removed bydirectly affects peptide translocation. Using an estab-
apyrase in nontransfected HtTa cells prior to measurement of pep-lished assay that monitors peptide translocation inde-
tide transport. Results arepresented as the mean of duplicate exper-
pendent of MHC class I binding by ConA precipitation iments (6 standard deviation).
of peptides glycosylated upon entry into the ER (Neefjes
et al., 1993) we compared TAP activity in nontransfected
HtTa cells or in cells stably transfected with US3, US11, 72 hr at a multiplicity of infection (moi) of 5, and peptide
ICP47, or US6 (Figure 3). No significant difference in the translocation was measured by the recovery of glycosy-
amount of glycosylated peptides was observed between lated 125I-labeled reporter peptide library. In contrast to
noninduced or induced US3 and US11 cells (Figure 3) wild-type HCMV, none of these deletion mutants inhib-
or U373 cells transfected with US2 (data not shown). ited TAP-mediated peptide translocation in infected
By contrast, peptide transport activity was completely HFF cells, whereas peptide translocation was blocked
inhibited in cells expressing US6, similar to ICP47 when a synthetic version of ICP47 (sICP47) was added
transfectants or after ATP removal. Since peptide trans- (Figure 4A).
location was inhibited independently of MHC class I Since the gene absent from all these mutant viruses
loading, we conclude that peptide loading and impaired is US6, a deletion mutant lacking this gene was con-
MHC class I transport are downstream events of TAP structed. HFF cells were infected for 72 hr at an moi of
inhibition by US6. 5 with the mutant lacking the US6 gene. As shown in
Figure 4B, the absence of the US6 gene product restored
TAP-dependent peptide translocation in HFF cells.US6 Inhibits TAP in HCMV-Infected Cells
These results clearly demonstrate that US6 is solelyRecently, it was demonstrated that TAP transport is
responsible for the inhibition of peptide translocation ininhibited during HCMV infection (Hengel et al., 1996).
HCMV-infected cells.Moreover, peptide translocation was restored upon de-
letion of a 15 kb fragment spanningUS1±US15. To inves-
tigate whether US6 alone or in combination with other Subcellular Localization of US6
The observed functional similarity between ICP47 andgenes encoded in this region is responsible for TAP
inhibition during HCMV infection, we analyzed peptide US6 contrasts with their different predicted protein
structure. ICP47 is a soluble protein that contains 89transport activity in cells infected with a series of HCMV
mutants (Jones et al., 1995) containing the deletions amino acids and that localizes to the cytosol (York et
al., 1994; FruÈ h et al., 1995), whereas the open readingIRS1±US6, US2±US11, and US6±US11 (Figure 4A). Hu-
man foreskin fibroblast (HFF) cells were infected either frame US6 encodes a predicted type I transmembrane
glycoprotein of 184 amino acids with some degree ofwith wild-type HCMV or with the deletion mutants for
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Figure 5. Subcellular Localization of US6
HtTa cells were transiently transfected with US6 and grown in the
absence of tetracycline for 48 hr. US6 was visualized using anti-
Figure 4. US6 Is Responsible for TAP Inhibition during HCMV In- US6N and goat-anti-rabbit rhodamine conjugate (Cappel). Calnexin
fection was stained with AF8 (Sugita and Brenner, 1994) and visualized with
goat-anti-mouse fluorescein isothiocyanate (Cappel). Nontrans-Translocation of a reporter peptide library was measured in HFF
fected cells that express calnexin but not US6 are indicated bycells infected with HCMV mutants containing deletions of multiple
arrows. The same microscopic fieldwas photographed atthe excita-genes within the IRS1±US11 region (A) or with only US6 deleted (B).
tion wavelengths of rhodamine (top), fluorescein (bottom), or bothPeptide transport assays were performed as described in Experi-
(middle).mental Procedures. As a control, peptide recovery after 0 min incu-
bation or after the addition of sICP47 was measured. HCMV mutants
IRS1-US6, US2-US11, US6-US11, as well as US6 have been de-
scribed previously (Jones et al., 1995). The ER-Luminal Domain of US6
Is Responsible for TAP Inhibition
Since TAP inhibition by an ER-resident protein has notsequence homology to the open reading frames US2±
been observed previously, we wanted to know whetherUS11 (Chee et al., 1990; Ahn et al., 1996a). To study the
US6 inhibits TAP and/or is retained in the ER via itssubcellular localization of US6, we raised antipeptide
cytoplasmic, transmembrane, or luminal domain. There-antibodies against the predicted luminal domain of US6
fore, we constructed a series of fusion proteins andand compared by immunofluorescence analysis its in-
examined their intracellular localization and transporttracellular localization with that of calnexin, an ER-resi-
as well as their ability to reduce MHC class I surfacedent chaperone (Degen and Williams, 1991). When HeLa
expression and peptide translocation (Figure 6). Whencells transiently transfected with US6 were probed with
the cytoplasmic domain of CD8 was replaced with thatantiserum US6-N, a perinuclear staining was observed
of US6, surface levels of MHC class I remained un-for transfected cells but not for nontransfected cells
changed (Figure 6, CD8US6). Moreover, the cytoplasmic(Figure 5, arrows). A similar pattern was observed both
tail of US6 was unable to prevent the intracellular trans-for transfected and nontransfected cells with the cal-
port of CD8, in contrast to the cytoplasmic tails of anexin-specific MAb AF8 (Figure 5, bottom). Moreover,
number of ER-resident proteins (Jackson et al., 1990).costaining indicated that both proteins localized to the
Thus it seems that the cytoplasmic tail of US6 is notsame compartment (Figure 5, middle). Thus, we con-
sufficient for either ER retention or TAP inhibition.clude that US6 is an ER-resident glycoprotein as ob-
To examine whether the luminal domain of US6 aloneserved for US3 (Ahn et al., 1996a), US11 (Wiertz et al.,
1996a) and a subpopulation of US2 (Wiertz et al., 1996b). would inhibit peptide transport, we replaced both the
ER-Luminal TAP Inhibition by HCMV US6
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luminal domain of US6 is responsible for both ER reten-
tion and TAP inhibition.
To examine whether the luminal domain needs to be
anchored in the membrane in order to inhibit TAP, we
fused the luminal domain of US6 to the sequence KDEL,
which retains soluble proteins in the ER. In addition, we
truncated the US6 luminal domain by introducing a stop
codon at amino acid position 139, before the predicted
transmembrane domain. As shown in Figure 6, both
US6KDEL and US6STOP remained EndoH sensitive, and
both were able to prevent peptide translocation and
thus class I surface expression. We conclude that the
luminal domain of US6 is responsible for both inhibition
of peptide translocation and ER retention of US6.
Association of US6 with the TAP/Class I Complex
It seemed likely that TAP inhibition and/or ER retention
involved a direct interaction between US6 and TAP.
However, neither of the two anti-US6 antisera coimmu-
noprecipitated TAP from lysates, even when mild deter-
gents were used for solubilization (data not shown). This
might be due to the possibility that these antisera are
not able to recognize a US6/TAP complex because their
epitopes are involved in TAP binding. Therefore, we
used an antiserum against the E19 cytoplasmic tail to
immunoprecipitate US6E19 from digitonin lysates of
transiently transfected HeLa cells. We modulated the
intracellular concentrations of both US6E19 and TAP
by using tetracycline or interferon-g, respectively. As a
control, we immunoprecipitated the TAP/class I com-
plex from HeLa cells using anti-TAP1 antiserum, which
coprecipitates both MHC class I heavy chain and b2-
microglobulin (Figure 7, lane 1) and at least two addi-
tional proteins (arrows) with molecular weights corre-
Figure 6. The Luminal Domain of US6 Is Sufficient for ER Retention sponding to calreticulin (top band) and tapasin (bottom
and MHC Class I Down-Regulation band), both of which are thought to be involved in class
HtTa cells were transiently transfected with the indicated constructs I binding to TAP (Sadasivan et al., 1996). Neither of these
in the absence of tetracycline. Thirty-six hours after transfection,
proteins was coprecipitated by anti-E19 from digitoninMHC class I surface expression was monitored by cytofluorometry
lysates of CD4E19-transfected cells (lane 2). In contrast,using MAb W6/32.
both TAP subunits as well as class I heavy chain and(Left) Results are graphically depicted as cell number versus mean
fluorescence (log scale). b2-microglobulin coprecipitated with US6E19, as shown
(Right) The US6 derivatives immunoprecipitated with anti-US6N by reprecipitation with the respective antibodies (Figure
from NP40 lysates of transiently transfected HtTa cells labeled for 7, lanes 8±11). Moreover, the two additional proteins
30 min (lanes 1 and 2) and chased for 4 hr (lanes 3 and 4). Lanes 2 were coprecipitated by anti-E19, indicating that US6
and 4 were treated with EndoH prior to SDS polyacrylamide gel
does not disrupt the TAP/class I complex. Interestingly,electrophoresis. Immunoprecipitation shown in the top panel was
increasing amounts of TAP/class I complex were copre-performed with anti-CD8; all other immunoprecipitations were car-
ried out with anti-US6N. Intracellular transport of CD8 is indicated cipitated upon decreasing US6E19 expression levels
by the molecular weight shift due to addition of sialic acid. Since (lane 3±7).
CD8 does not contain N-linked carbohydrates, it is not affected by We interpret this result as an indication of a specific
EndoH. Compared to nontransfected HtTa cells, peptide transport saturable binding of US6, because upon saturation the
activity was reduced 50%±63% in all transfectants except for CD8-
ratio of free versus TAP-bound US6 increases with theUS6, in which no reduction was observed (data not shown).
intracellular concentration of US6. At high expression
levels, relatively more unbound US6 will be precipitated
if limiting amounts of the E19-specific antiserum arepredicted transmembrane domain and the cytoplasmic
tail of US6 with that of CD8 and adenovirus E19, respec- used, as is the case in the experiment shown in Figure
7. A very similar observation was made with ICP47: thetively. The resulting fusion protein US6E19 remained
EndoH sensitive and down-regulated MHC class I sur- majority of ICP47 remains free in the cytosol upon over-
expression whereas most ICP47 is bound to TAP at lowface expression as a result of TAP inhibition (Figure 6).
Interestingly, ER retention as well as TAP inhibition was concentrations (FruÈ h et al., 1995). Since binding to TAP
is saturable it is unlikely that US6 is retained in the ERalso observed for the construct US6E19D, which con-
tains a deletion in the ER retention signal of the E19 tail by binding to TAP, because US6E19 does not acquire
EndoH resistance regardless of its expression levels(Jackson et al., 1990). These results suggested that the
Immunity
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Figure 8. Peptide Binding to TAP in US6-Transfected HeLa Cells
Untransfected HtTa cells or HtTa cells stably transfected with US6
or ICP47 were grown in the presence or absence of tetracycline prior
to streptolysin O permeabilization and incubation with photoreactive
peptide KYWANATRSGL together with 1 mM purified recombinant
His-ICP47 as described (Ahn et al., 1996b). After ultraviolet cross-
linking, heterodimeric TAP molecules were precipitated with anti-
TAP1 antiserum and separated by SDS polyacrylamide gel electro-
phoresis. The relative positions of TAP1 and TAP2 are indicated.
expressing US6 (Figure 8). As a control we used ICP47-
transfected and nontransfected HeLa cells. In agree-
ment with our previous observations (Ahn et al., 1996b),
peptides could not be cross-linked to TAP isolated from
ICP47-expressing cells (Figure 8, lane 8) or from HeLa
cells treated with purified recombinant His-ICP47 (Fig-
ure 8, lane 3). By contrast, US6 expression did not pre-
vent peptide binding (lane 5). Moreover, ICP47 bindingFigure 7. The Luminal Domain of US6 Interacts with TAP
to TAP was not affected by US6, since His-ICP47 inhib-
HtTa cellwere nontransfected (lane 1) or transfected with CD4E19.p-
ited peptide binding in US6-expressing cells (lane 6).CMUII (Jackson et al., 1990) (lane 2) or pUHG10.3- US6E19 (lane
We conclude that US6 interacts with a different domain3±7). Two days after transfection, cells were metabolically labeled
for 16 hr and proteins were solubilized in 1% digitonin and immuno- of TAP compared to ICP47 and that US6 inhibits TAP
precipitated with anti-TAP1 (lane 1) or anti-E19 antiserum (Nilsson by a different mechanism.
et al., 1989) (lane 2±7) and separated by SDS polyacrylamide gel
electrophoresis (lanes 1±7). A fraction of the anti-E19 precipitate Discussion
from US6E19-transfected cells was dissolved in 1% SDS and repre-
cipitated with anti-TAP1 (lane 8), anti-TAP2 (lane 9), K455 (13) (anti-
The HCMV US region encodes a family of eight glycopro-class I [Andersson et al., 1985]) (lane 10), or anti-US6N (lane 11).
(Lanes 1±7 and 8±11 are from different gels; hence the slightly differ- teins (US2, US3, US6, and US7±US11), all of which share
ent mobility of b2-microglobulin). Prior to immunoprecipitation, cells some degree of sequence homology (Chee et al., 1990;
were grown for 24 hr without tetracycline (lanes 1±3) or with 0.0001, Ahn et al., 1996a). Our data show that four members of
0.001, 0.01, or 0.1 mg/ml tetracycline (lanes 4±7) to achieve decreas- this family (US2, US3, US6, and US11) are independently
ing expression levels of US6E19. Proteins that are part of the TAP/
capable of preventing MHC class I surface expression.class I complex as well as CD4E19 are indicated on the left. All
Although US7±US10 had no effect in our assay, we can-other protein bands are nonspecifically immunoprecipitated since
they are present in all precipitations. Cells were treated for 24 hr with not rule out the possibility that a potential interference
interferon-g (1000 U/ml) prior to labeling to increase TAP expression. of US7±US10 with the class I pathway remained unde-
tected by our analysis. For instance, they could affect
class I haplotypes not present in HeLa cells or their
(Figures 6 and 7). However, the interaction of US6 with influence may be too subtle to be detectable in transient
the TAP/class I complex might be required for the experiments. However, since none of the three pre-
blocking of peptide translocation by TAP. viously known evasion molecules (US2, US3, and US11)
escaped detection by this approach, it seems likely that
US7±US10 have other functions unrelated to antigenUS6 Does Not Inhibit Peptide Binding to TAP
The association of US6 with the luminal portion of TAP presentation. Thus, our data suggest that HCMV con-
tains a total of four gene products interfering with theis in contrast to ICP47, which approaches TAP from the
cytosol. These different modes of interaction might be MHC class I antigen presentation pathway. The different
mechanisms by which US2, US3, and US11 prevent anti-reflected in different molecular mechanisms of TAP inhi-
bition. We demonstrated previously that ICP47 does not gen presentation have been described previously (Ahn
et al., 1996a; Jones et al., 1996; Wiertz et al., 1996a,inhibit ATP binding to TAP but competes with peptides
for binding to the substrate-binding site of TAP (Ahn et 1996b). Our finding that US6 inhibits peptide transloca-
tion by TAP, in contrast to all other US proteins, clearlyal., 1996b). Likewise, we did not observe an inhibition
of ATP binding to TAP from US6-expressing cells (data separates the molecular action of US6 from the other
US protein family members.not shown). To test whether US6 would interfere with
peptide binding, we added labeled peptides carrying a TAP inhibition has also been observed for the herpes
simplex virus protein ICP47 (FruÈ h et al., 1995; Hill et al.,photo-cross-linker to streptolysin O±permeabilized cells
ER-Luminal TAP Inhibition by HCMV US6
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1995). However, several lines of evidence indicate that retention by US3 during immediate early times and their
destruction by US11 and US2 during early and late timesthe molecular mechanism of TAP inhibition by US6 dif-
of infection. The reason why HCMV has adopted suchfers from that of ICP47. During peptide translocation,
a sequential strategy to escape immune detection istwo steps clearly can be separated experimentally. The
presently not known. A possible explanation for the op-initial binding of peptides to TAP does not require ATP
eration of several genes in different ways might be that(Androlewicz and Cresswell, 1994; Androlewicz et al.,
each mechanism is leaky with respect to certain MHC1994; Van Endert et al., 1994), and ATP binds to isolated
class I haplotypes or certain peptides. For instance, US6ATP-binding domains of both TAP1 and TAP2 (MuÈ ller
will be unable to prevent TAP-independent presentationet al., 1994; Wang et al., 1994). However, peptide translo-
of signal sequences generated inside the ER by signalcation seems tobe coupled toATP-binding and hydroly-
sequence peptidases (Henderson et al., 1992; Wei andsis, since peptide transport is inhibited by nonhydrolyz-
Cresswell, 1992). Thus, the different modes of actionable ATP analogs (Neefjes et al., 1993; Shepherd et
might be a backup system to ensure complete preven-al., 1993). Thus, following peptide binding, TAP might
tion of MHC class I antigen presentation and thus T cellundergo ATP-driven conformational changes, releasing
recognition of HCMV infected cells.peptides from the substrate-binding site to enter the
translocation channel. Whereas ICP47 interferes with
Experimental Proceduresthe first step by competing with peptides for binding
(Ahn et al., 1996b; Tomazin et al., 1996), US6 seems to
Constructs
interfere with the subsequent step(s). It might be that The cloning and expression of US3, US11, and ICP47 have been
binding of US6 to the TAP/class I complex affects TAP described (FruÈ h et al., 1995; Ahn et al., 1996a). The open reading
frames US2, US4, US5, US6, US7, US8, US9, and US10 (Chee etconformation, thereby prohibiting peptides from enter-
al., 1990) were amplified by polymerase chain reaction using HCMVing the ER. Thus, US6 might be a useful tool to further
genomic cosmid pCM 1052 as template (Fleckenstein et al., 1982).dissect the molecular steps of peptide translocation.
All 59-end primers contained the SacII restriction site CCGCGG fol-
The different subcellular localization of ICP47 com- lowed by the sequence CCACCATG, corresponding to a consensus
pared to that of US6 together with their different modes initiation signal (Kozak, 1984). The underlined start codon corre-
sponded to the first three nucleotides of each open reading frameof action also supports the hypothesis that the initial
except for US4, for which the start codon was supplied by the primerpeptide binding occurs on the cytoplasmic side of TAP.
since the US4 open reading frame does not contain a start codonThis hypothesis was based on the findings that bound
by itself. The 59-end primers extended 20±30 nucleotides into the
peptides are cross-linked to TAP residues correspond- respective coding region, matching exactly the published sequence
ing to regions of the TAP sequence predicted, by theo- (Chee et al., 1990), with the exception of US7, for which a silent
mutation was introduced by replacing the G at position 6 of theretical considerations, to be on the cytoplasmic side
coding region with a T in order to remove a BamHI recognition site.(Nijenhuis and HaÈ mmerling, 1996a; Nijenhuis et al.,
All 39-end primers matched the last 20±30 nucleotides of the coding1996b). Thus, our finding that the ER-luminal portion of
sequences followed by a stop codon and a BamHI restriction site.
US6 is responsible for TAP inhibition is consistent with Amplified DNA fragments were inserted as SacII/ Bam HI into the
the inability of US6 to prevent peptide binding to TAP. tetracycline-inducible expression vector pUHG10.3 (Gossen and
Bujard, 1992).Although all of the US proteins studied so far localize
Modified US6 constructs were obtained by primer-directed PCRto the ER (Ahn et al., 1996a; Wiertz et al., 1996a) (US2
mutagenesis. CD8US6 contains the luminal and transmembrane do-is present both in the ER and cytosol [Wiertz et al.,
mains of CD8 (to amino acid 212) followed by the predicted cyto-
1996b]), it is not known what causes their ER retention. plasmic tail of US6 (amino acid sequence ESTGRGIRRCGS).
In analogy to the adenovirus immune evasion protein US6E19 and US6E19D contain amino acids 1±144 of wild-type US6
E19, it seemed possible that the ER-retention motif is followed by the transmembrane domain of CD8 (amino acids 182±
212 of wild-type CD8) and the cytoplasmic tail of E19 (amino acidseparated from the business end of the molecules by
sequence RSFIDEKKMP [E19] or KMP [E19D] [Jackson et al., 1990]).the transmembrane domain. However, the cytoplasmic
To generate US6KDEL, the amino acids KDEL were fused with aminotails of US6 (Figure 6) or any of the other US proteins acids 1±144 of US6. US6STOP was constructed by introducing a
(our unpublished data) are insufficient for ER retention. stop codon at amino acid position 139.
Moreover, in the case of US6, both TAP binding and
AntibodiesER retention are mediated by the luminal domain. As
Antisera specific for US6 were raised against the synthetic peptidesdiscussed above, TAP binding cannot account for ER
SSRDPKTLLSLSPRQQA (US6-N) and TYESTGRGIRRCGS (US6-C).retention of US6. Therefore, we must assume that US6
Anti-TAP1 and anti-TAP2 antibodies were generated against the
is retained by another mechanism, for instance similar carboxy-terminal 21 amino acid residues of human TAP1 (Trowsdale
to that for misfolded cellular or viral proteins. Such un- et al., 1990) and human TAP2 (Kelly et al., 1992), respectively. In
addition, the peptides contained a cysteine at their amino terminusfolded proteins are usually found in association with ER-
for cross-linking to bovine serum albumin using N-succinimidyl-3-resident chaperones (Hammond and Helenius, 1994).
(2-pyridyldithio)propionate (Pierce). Rabbits were injected with 500However, the relevance of this association for ER reten-
mg of the peptide±bovine serum albumin in complete Freund's
tion of unfolded proteins is not known. Further work will adjuvants, followed by several injections of 100 mg in incomplete
be needed to clarify this point. adjuvants. Antibodies to the carboxy-terminal region of E19 been
During the infectious cycle of HCMV, the mRNA for described previously (Nilsson et al., 1989). MAb AF8 recognizing
human calnexin was a kind gift from M. Brenner (Sugita and Brenner,US6 is most abundant at late times postinfection (Jones
1994).and Muzithras, 1991). Accordingly, TAP inhibition has
been observed to increase steadily during infection and
Viral Infections
is complete only during the late phase of infection HCMV wild-type strain AD169 was obtained from the American Type
(Hengel et al., 1996). Thus, the inhibition of peptide load- Culture Collection, and HCMV mutants were constructed as pre-
viously described (Jones et al., 1995). HFF cells were cultured asing onto MHC class I molecules seems to follow their
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Transfections and Stable Cell Lines
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References(HtTa cells) (Gossen and Bujard, 1992) were transfected with 24 mg
plasmid DNA by Ca21/PO42 precipitation as described by Jackson
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Metabolic Labeling and Immunoprecipitation
Androlewicz, M.J., and Cresswell, P. (1994). Human transporters
For pulse-chase experiments, 106 cells were methionine starved for
associated with antigen processing possess a promiscuous pep-
30 min prior to pulse labeling for the indicated times using 0.5 mCi
tide-binding site. Immunity 1, 7±14.
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